未名醫藥(002581.SZ):因合資經營合同解除 未名天源擬將4600萬元自有設備及技術轉讓予營口化工
格隆匯 10 月 20日丨未名醫藥(002581.SZ)公佈,全資子公司山東未名天源生物科技有限公司(以下簡稱“未名天源”)於2019年2月14日簽訂《合資經營合同》。後與淄博魯華泓錦新材料股份有限公司、淄博東部化工建設發展有限公司進行多次商談推動,因不可歸責於合同任何一方的原因(不可抗力),該《合資經營合同》已於2020年9月解除,合同各方未實繳出資、未開展任何經營活動。
近期,未名天源與營口營新化工科技有限公司(以下簡稱“營口化工”)簽訂了《設備轉讓合同》,合同約定未名天源將自有設備及技術轉讓給營口化工,交易價格為人民幣4600萬元。
本次交易不構成《上市公司重大資產重組管理辦法》規定的重大資產重組,本次交易也不構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.